Loading
Genetic and Kidney Cyst Diseases / CRISPR and Genetic Engineering · Journal article
Scientific Records · July 18, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of emerging gene editing approaches (CRISPR-Cas, base editing, prime editing, RNA targeting) for cystic fibrosis correction. The source reports encouraging preclinical results in patient-derived organoids and animal models but identifies substantial unresolved challenges—off-target effects, immune responses, delivery barriers, and long-term genomic stability—and does not present clinical trial data or quantitative efficacy estimates.
Narrative review. Patients with cystic fibrosis, particularly those with rare or severe CFTR mutations; preclinical studies used patient-derived organoids and animal models..
Preclinical studies in patient-derived organoids, airway epithelial cells, stem cell models, and animal systems demonstrated encouraging results in restoring CFTR function CFTR modulators and symptomatic therapies have improved outcomes but remain mutation-specific and do not provide definitive cure, particularly for rare or severe mutations Challenges to clinical translation include off-target effects, immune responses, delivery barriers in airway environment, long-term genomic stability, and ethical considerations
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review does not yet provide evidence to guide clinical practice. It maps the therapeutic landscape and identifies gene editing as a potential future avenue toward curative treatment, but acknowledges that multiple safety and delivery barriers must be resolved before clinical translation.
A narrative review of emerging gene editing technologies with preclinical evidence only; no clinical trial data, efficacy figures, or comparative results are reported.
As stated by the source record.
This review does not yet provide evidence to guide clinical practice. It maps the therapeutic landscape and identifies gene editing as a potential future avenue toward curative treatment, but acknowledges that multiple safety and delivery barriers must be resolved before clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cystic fibrosis (CF) is a life threatening autosomal recessive disorder caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride and bicarbonate ion channel essential for epithelial fluid homeostasis.Dysfunctional CFTR impairs ion transport across epithelial surfaces, leading to dehydrated mucus, chronic respiratory infections, progressive lung damage, pancreatic insufficiency, and multisystem complications.Although CFTR modulators and symptomatic therapies have significantly improved patient outcomes and survival, they remain mutation specific and do not provide a definitive cure, particularly for patients with rare or severe mutations.Recent advances in genome engineering have introduced promising strategies for directly correcting CFTR mutations at the DNA and RNA levels.Technologies such as CRISPR-Cas systems, base editing, prime editing, and RNA targeting approaches offer the potential to repair disease causing mutations rather than merely alleviating symptoms.Preclinical studies in patient derived organoids, airway epithelial cells, stem cell models, and animal systems have demonstrated encouraging results in restoring CFTR function.In parallel, the development of viral and non-viral delivery systems has improved the targeted delivery of gene editing components to respiratory tissues.Despite these advancements, several challenges remain, including off-target effects, immune responses, delivery barriers in the airway environment, long term genomic stability, and ethical considerations related to genome modification.Ongoing progress in precision medicine, artificial intelligence assisted editing design, and personalized therapeutic strategies is expected to enhance safety and efficiency.This review summarizes the pathophysiology of CFTR dysfunction and critically evaluates emerging gene editing technologies for cystic fibrosis, highlighting their therapeutic potential, current limitations, and future clinical prospects toward a durable and potentially curative treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.